• MLKL Polymerization Drives Lysosomal Membrane Permeabilizati

  2026-05-31

  This study defines how MLKL polymerization at the lysosomal membrane induces permeabilization, releasing cathepsin proteases and driving necroptosis. The findings clarify the mechanistic link between MLKL amyloid-like structures, lysosomal disruption, and regulated cell death, with immediate implications for understanding cell death in disease contexts.

• Epalrestat: Mechanistic Advances for Neuroprotection in PD

  2026-05-30

  Explore how Epalrestat, a high-purity aldose reductase inhibitor, is reshaping translational research from diabetic neuropathy to neurodegeneration. This article unpacks the molecular rationale, experimental breakthroughs, and strategic guidance for leveraging Epalrestat in oxidative stress and Parkinson’s disease models, synthesizing recent findings on KEAP1/Nrf2 pathway activation with practical workflow insights. Go beyond product listings—discover a roadmap for innovation at the intersection of metabolism and neuroprotection.

• BH3 Mimetics Target Chemotherapy-Induced Senescence in TP53

  2026-05-29

  This study demonstrates that BH3 mimetics can selectively eliminate chemotherapy-induced senescent tumor cells in TP53 wild-type breast cancer, overcoming a major barrier to effective therapy. The findings highlight the need for combined BCL-XL and MCL1 inhibition to fully induce apoptosis in these persistent, relapse-promoting cell populations.

• Spleen-Targeted mRNA Vaccine Induces TLS via ISG15+ CD8+ T C

  2026-05-29

  Lin et al. present a spleen-targeted neoantigen mRNA vaccine (STNvac) that elicits potent antitumor immunity in hepatocellular carcinoma by driving ISG15+ CD8+ T cell responses and tertiary lymphoid structure (TLS) formation. This approach reveals new mechanistic insights into organ-targeted mRNA vaccination and highlights translational opportunities for improving immunotherapy in solid tumors.

• GI 254023X: Applied ADAM10 Inhibitor Workflows & Optimizatio

  2026-05-28

  GI 254023X sets a new standard for selective ADAM10 inhibition, empowering researchers to dissect Notch1 signaling, apoptosis, and vascular integrity with unprecedented specificity. Explore robust experimental strategies, troubleshooting insights, and translational advantages that distinguish this tool from conventional metalloprotease inhibitors.

• Sulfaphenazole: Expanding Beyond CYP2C9 Inhibition in Antiba

  2026-05-28

  Explore Sulfaphenazole as a selective CYP2C9 inhibitor and multifaceted research tool. This in-depth analysis uncovers advanced antibacterial mechanisms, translational vascular applications, and practical assay guidance—distinct from other reviews.

• Acridine Orange hydrochloride: Technical Guide for Nucleic A

  2026-05-27

  Acridine Orange hydrochloride enables differential staining of DNA and RNA in fixed or live cell workflows, supporting precise cell cycle analysis and apoptosis detection by flow cytofluorometry. It is not suitable for long-term solution storage or for applications outside nucleic acid-targeted cytochemistry.

• Biochemical Characterization of GOB-38 β-Lactamase in E. ano

  2026-05-27

  This study identifies and characterizes GOB-38, a novel metallo-β-lactamase in Elizabethkingia anophelis, revealing its broad substrate specificity and structural features that underlie resistance to multiple β-lactam antibiotics. These findings have significant implications for understanding multidrug resistance evolution and the risk of resistance gene transfer among clinically important pathogens.

• Pumilio-Mediated KCNK3 Suppression Drives Pulmonary Hyperten

  2026-05-26

  This study uncovers a HIF1α-PUM2-KCNK3 regulatory axis as a pivotal driver of pulmonary hypertension via post-transcriptional repression of KCNK3 in pulmonary artery smooth muscle cells. The findings highlight new therapeutic avenues targeting Pumilio proteins to restore potassium channel function and attenuate vascular remodeling.

• Resibufogenin Inhibits NLRP3 Inflammasome to Mitigate Athero

  2026-05-26

  The referenced study reveals that resibufogenin (RBG) offers substantial protection against atherosclerosis in ApoE-/- mice by specifically blocking NLRP3 inflammasome assembly. This mechanism curbs inflammatory responses, macrophage foam cell formation, and plaque development, underscoring RBG's potential as a new therapeutic avenue for cardiovascular inflammation.

• Dutasteride: Accelerating Translational Gains in Prostate Re

  2026-05-25

  This thought-leadership article explores Dutasteride’s role as a dual 5-alpha-reductase inhibitor, offering mechanistic insights and strategic guidance for translational researchers working in prostate cancer and BPH. Integrating the latest findings, it examines how Dutasteride catalyzes experimental rigor, protocol optimization, and future innovation, while positioning APExBIO’s Dutasteride as a benchmark for research-grade androgen pathway modulation.

• Dasatinib Monohydrate in Advanced Cancer Assembloids: Protoc

  2026-05-25

  Dasatinib Monohydrate (BMS-354825) unlocks new dimensions in kinase pathway research and personalized drug screening, especially within sophisticated assembloid models. This article translates recent breakthroughs and troubleshooting insights into practical workflows, empowering researchers to dissect resistance mechanisms and optimize experimental reproducibility.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Applied Workflows

  2026-05-24

  10058-F4 enables precise, mechanism-based targeting of c-Myc-Max function for apoptosis and stem cell research. Learn how to optimize experimental design, troubleshoot common pitfalls, and translate reference study insights into actionable protocols.

• Machine Learning Predicts Lipid Nanoparticles for mRNA Vacci

  2026-05-23

  This study pioneers the use of machine learning to predict and optimize lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, reducing reliance on traditional experimental screening. The model accurately identifies key ionizable lipid structures, offering a scalable path for efficient mRNA vaccine development.

• Tumor-Targeted PAD4 Inhibition via PBA: Mechanistic Advances

  2026-05-22

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors that achieve highly selective inhibition of tumor and neutrophil PAD4 activity. By targeting the PAD4-H3cit-NETs pathway, these inhibitors suppress tumor growth and metastasis with improved safety, providing a mechanistic foundation for next-generation antitumor therapeutics.

462 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page